Evidence map›Paper›PMID 36891649›Full record

Trial reportThe American journal of psychiatry2023

A Novel Psychosocial Intervention for Motivational Negative Symptoms in Schizophrenia: Combined Motivational Interviewing and CBT.

L Felice Reddy, Shirley M Glynn, Jessica E McGovern, Catherine A Sugar, Eric A Reavis, Michael F Green

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in The American journal of psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Treating Pathologies of the Will.The American journal of psychiatry · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

L Felice ReddyDepartment of Veterans Affairs VISN 22 Mental Illness Research, Education, and Clinical Center, Los Angeles (Reddy, Glynn, McGovern, Green); UCLA Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, Los Angeles (Reddy, Glynn, McGovern, Sugar, Reavis, Green); Department of Biostatistics, UCLA Fielding School of Public Health, Los Angeles (Sugar).
Shirley M GlynnDepartment of Veterans Affairs VISN 22 Mental Illness Research, Education, and Clinical Center, Los Angeles (Reddy, Glynn, McGovern, Green); UCLA Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, Los Angeles (Reddy, Glynn, McGovern, Sugar, Reavis, Green); Department of Biostatistics, UCLA Fielding School of Public Health, Los Angeles (Sugar).
Jessica E McGovernDepartment of Veterans Affairs VISN 22 Mental Illness Research, Education, and Clinical Center, Los Angeles (Reddy, Glynn, McGovern, Green); UCLA Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, Los Angeles (Reddy, Glynn, McGovern, Sugar, Reavis, Green); Department of Biostatistics, UCLA Fielding School of Public Health, Los Angeles (Sugar).
Catherine A SugarDepartment of Veterans Affairs VISN 22 Mental Illness Research, Education, and Clinical Center, Los Angeles (Reddy, Glynn, McGovern, Green); UCLA Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, Los Angeles (Reddy, Glynn, McGovern, Sugar, Reavis, Green); Department of Biostatistics, UCLA Fielding School of Public Health, Los Angeles (Sugar).
Eric A ReavisDepartment of Veterans Affairs VISN 22 Mental Illness Research, Education, and Clinical Center, Los Angeles (Reddy, Glynn, McGovern, Green); UCLA Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, Los Angeles (Reddy, Glynn, McGovern, Sugar, Reavis, Green); Department of Biostatistics, UCLA Fielding School of Public Health, Los Angeles (Sugar).
Michael F GreenDepartment of Veterans Affairs VISN 22 Mental Illness Research, Education, and Clinical Center, Los Angeles (Reddy, Glynn, McGovern, Green); UCLA Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, Los Angeles (Reddy, Glynn, McGovern, Sugar, Reavis, Green); Department of Biostatistics, UCLA Fielding School of Public Health, Los Angeles (Sugar).
West Los Angeles College · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveNegative symptoms are a primary cause of disability in schizophrenia for which there are no established pharmacotherapies. This study evaluated a novel psychosocial intervention that combined two evidence-based practices-motivational interviewing and cognitive-behavioral therapy (MI-CBT)-for the treatment of motivational negative symptoms.

methodsSeventy-nine participants with schizophrenia and moderate to severe negative symptoms were included in a randomized controlled trial comparing the 12-session MI-CBT treatment with a mindfulness control condition. Participants were assessed at three time points through the study period, which included 12 weeks of active treatment and 12 weeks of follow-up. The primary outcome measures were motivational negative symptoms and community functioning; the secondary outcomes included a posited biomarker of negative symptoms: pupillometric response to cognitive effort.

resultsCompared with the control group, participants in the MI-CBT group showed significantly greater improvements in motivational negative symptoms over the acute treatment period. Their gains relative to baseline were maintained at follow-up, although the differential benefit relative to control subjects was attenuated. There were nonsignificant effects toward improvements in community functioning and differential change in the pupillometric markers of cognitive effort.

conclusionsThe results show that combining motivational interviewing with CBT yields improvements in negative symptoms, a feature of schizophrenia generally thought of as resistant to intervention. Motivational negative symptoms not only responded to the novel treatment, but the gains were maintained over the follow-up period. Implications for future studies and for improving the generalization of the negative symptom gains to daily functioning domains are discussed.

Indexed as

Cognitive Behavioral TherapyMindfulnessMotivational InterviewingSchizophreniaHumansPsychosocial InterventionBehavioralPsychotherapySchizophrenia Spectrum and Other Psychotic Disorders

Identifiers

PMID36891649
OpenAlexW4323652910

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.